Search results
Praluent vs. Repatha: Similaries and Differences
Verywell Health via Yahoo News· 3 months agoPraluent and Repatha are PCSK9 inhibitors that can lower low-density lipoprotein (LDL, or "bad") cholesterol levels in certain people. Though similar,...
New medication given every 1-3 months may slash stubborn high cholesterol
NewMediaWire via Yahoo Finance· 7 months agoResearch Highlights: While currently available PCSK9 inhibitor medications to lower cholesterol must...
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
Zacks via Yahoo Finance· 1 year agoThis week, Eli Lilly’s LLY candidate, solanezumab, failed to prevent Alzheimer’s in a study. Merck’s...
Amgen Moves to Dismiss Regeneron's Antitrust Case Regarding Cholesterol Drug
Benzinga via Yahoo Finance· 2 years agoSince their PCSK9 drugs to lower bad cholesterol won FDA approvals in 2015, Amgen Inc (NASDAQ: AMGN)...
How Gene Editing Could Help Solve the Problem of Poor Cholesterol
Time via Yahoo News· 2 years agoCredit - vchal—Getty Images Cardiovascular disease is the leading cause of death in the U.S. and...
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
Investor's Business Daily· 2 years agoVerve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high...
Could This Be Merck's Next Blockbuster Drug?
Motley Fool· 1 year agoEarlier this month, Merck (NYSE: MRK) announced positive results from a clinical trial of its cholesterol-lowering drug candidate MK-0616. With the...
Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels
Exec Edge via Yahoo Finance· 4 months agoBy Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL...
Patient Dies After Being Gene-Edited to Have Lower Cholesterol
Futurism via Yahoo News· 7 months agoResearchers have been able to reduce dramatically the level of bad cholesterol in human subjects...
Researchers developed a gene-editing technology that reduces 'bad' cholesterol
Engadget· 7 months agoIn a trial run by Verve Therapeutics, a Cambridge–based biotech company, researchers discovered that...